(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 173.22% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Nyxoah Sa's revenue in 2025 is $4,914,130.On average, 4 Wall Street analysts forecast NYXH's revenue for 2025 to be $567,285,056, with the lowest NYXH revenue forecast at $210,341,229, and the highest NYXH revenue forecast at $836,873,645. On average, 4 Wall Street analysts forecast NYXH's revenue for 2026 to be $1,880,420,648, with the lowest NYXH revenue forecast at $1,250,070,651, and the highest NYXH revenue forecast at $3,192,919,977.
In 2027, NYXH is forecast to generate $3,974,214,134 in revenue, with the lowest revenue forecast at $3,927,242,916 and the highest revenue forecast at $4,021,185,352.